» Articles » PMID: 35267449

Expression of MiR-24-1-5p in Tumor Tissue Influences Prostate Cancer Recurrence: The PROCA- Study

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Mar 10
PMID 35267449
Authors
Affiliations
Soon will be listed here.
Abstract

The role of miR-24-1-5p and its prognostic implications associated with prostate cancer are mainly unknown. In a population-based cohort, the Prostate Cancer Study throughout life (PROCA-life), all men had a general health examination at study entry and were followed between 1994 and 2016. Patients with available tissue samples after a prostatectomy with curative intent were identified (n = 189). The tissue expression of miR-24-1-5p in prostate cancer was examined by in situ hybridization (ISH) in tissue microarray (TMA) blocks by semi-quantitative scoring by two independent investigators. Multivariable Cox regression models were used to study the associations between miR-24-1-5p expression and prostate cancer recurrence. The prostate cancer patients had a median age of 65.0 years (range 47−75 years). The Cancer of the Prostate Risk Assessment Postsurgical Score, International Society of Urological Pathology grade group, and European Association of Urology Risk group were all significant prognostic factors for five-year recurrence-free survival (p < 0.001). Prostate cancer patients with a high miR-24-1-5p expression (≥1.57) in the tissue had a doubled risk of recurrence compared to patients with low expression (HR 1.99, 95% CI 1.13−3.51). Our study suggests that a high expression of miR-24-1-5p is associated with an increased risk of recurrence of prostate cancer after radical prostatectomy, which points to the potential diagnostic and therapeutic value of detecting miR-24-1-5p in prostate cancer cases.

Citing Articles

Uncovering essential anesthetics-induced exosomal miRNAs related to hepatocellular carcinoma progression: a bioinformatic investigation.

Huang N, Fang J, Du F, Zhou J, Li Y, Zhang X BMC Med Genomics. 2024; 17(1):154.

PMID: 38840234 PMC: 11155038. DOI: 10.1186/s12920-024-01922-7.


Early to sustained impacts of lethal radiation on circulating miRNAs in a minipig model.

Chakraborty N, Holmes-Hampton G, Gautam A, Kumar R, Hritzo B, Legesse B Sci Rep. 2023; 13(1):18496.

PMID: 37898651 PMC: 10613244. DOI: 10.1038/s41598-023-45250-9.

References
1.
Watahiki A, Wang Y, Morris J, Dennis K, ODwyer H, Gleave M . MicroRNAs associated with metastatic prostate cancer. PLoS One. 2011; 6(9):e24950. PMC: 3184096. DOI: 10.1371/journal.pone.0024950. View

2.
Lynch S, McKenna M, Walsh C, McKenna D . miR-24 regulates CDKN1B/p27 expression in prostate cancer. Prostate. 2016; 76(7):637-48. DOI: 10.1002/pros.23156. View

3.
Hashimoto Y, Shiina M, Kato T, Yamamura S, Tanaka Y, Majid S . The role of miR-24 as a race related genetic factor in prostate cancer. Oncotarget. 2017; 8(10):16581-16593. PMC: 5369986. DOI: 10.18632/oncotarget.15016. View

4.
Weidle U, Epp A, Birzele F, Brinkmann U . The Functional Role of Prostate Cancer Metastasis-related Micro-RNAs. Cancer Genomics Proteomics. 2018; 16(1):1-19. PMC: 6348398. DOI: 10.21873/cgp.20108. View

5.
Li X, Han X, Wei P, Yang J, Sun J . Knockdown of lncRNA CCAT1 enhances sensitivity of paclitaxel in prostate cancer via regulating miR-24-3p and FSCN1. Cancer Biol Ther. 2020; 21(5):452-462. PMC: 7515504. DOI: 10.1080/15384047.2020.1727700. View